Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non–Small Cell Lung Cancer
Conclusions:
Nab-paclitaxel monotherapy with a dose and schedule suitable for outpatients showed high ORR, long median PFS, and acceptable toxicity for patients with previously treated NSCLC. This dosage method may be useful for selected patients.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
More News: Abraxane | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Nanotechnology | Non-Small Cell Lung Cancer | Study | Toxicology